The US Food and Drug Administration (FDA) approved its first three breakthrough designation (BTD) drugs; promising phase 2 data were reported for several other BTD drugs in hepatitis C. The last quarter of 2013 was also significant for the approval of two new drugs for pulmonary hypertension. Regulators gave negative decisions on Lemtrada (alemtuzumab) in multiple sclerosis and masitinib for gastrointestinal tumors. Early 2014 will be a busy time for the FDA as a large number of new medical entities (NMEs) have PDUFA dates.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline 4Q13. Nat Biotechnol 32, 125 (2014). https://doi.org/10.1038/nbt.2815
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2815